Imperial College London

Dr Mark P. Lythgoe

Faculty of MedicineDepartment of Surgery & Cancer

Clinical Research Fellow







Institute of Reproductive and Developmental BiologyHammersmith Campus





Dr Mark P. Lythgoe is an Academic Clinical Fellow in Medical Oncology and Pharmacist.  He is currently undertaking a PhD (primary supervisor Dr Jonathan Krell) exploring the cancer microbiome and live oral biotherapeutics as novel anti-cancer agents. Presently he oversees (principal investigator Dr Krell) the Imperial sponsored MICROBIOME trial (NCT03934827) with industry partner 4D Pharma exploring use of a live oral biotherapeutics (MRx0518) in patients with solid tumours awaiting surgical removal of the tumour. 

After studying Pharmacy at Aston University, Mark went on to graduate with a duel distinction in Medicine from Kings College London.  After completion of junior doctor posts in west London, he is now undertaking specialist academic training in Medical Oncology. He has also undertaken an academic clinical fellowship placement with Dr Rohini Sharma, exploring prognostic indices in high grade neuroendocrine tumours and PET imaging in a range of solid cancers, utilizing novel radionuclides to predict therapy responses. 

He has a range of academic interests including translational clinical trial development, cancer microbiome modulation as a therapeutic strategy, healthcare policy, improving clinical trial access and meta-research. He has also been a member of the Joint Formulary Committee for the British National Formulary (BNF) for 8 years.

He received an American Society of Cancer Merit Award in 2021 and has authored papers in the JAMA Oncology, Nature Reviews Clinical Oncology, Journal of Clinical Oncology, and Trends in Pharmacological Sciences.  He also reviews manuscripts for several journals including Cancer, Scientific Reports, Trends in Pharmacological Sciences and European Journal of Cancer. 



Lythgoe M, Sullivan R, Blagden S, 2023, UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver New anti-cancer therapies, The Lancet Oncology, Vol:24, ISSN:1213-9432, Pages:963-966

Lythgoe M, 2023, Another setback for cancer research in the UK, Bmj: British Medical Journal, ISSN:0959-535X

Aboagye E, Aravind P, Popat S, et al., 2023, A subset of non-small cell lung cancer patients treated with pemetrexed show 18f-fluorothymidine ‘flare’ on positron emission tomography, Cancers, Vol:15, ISSN:2072-6694, Pages:1-14

Lythgoe M, Sullivan R, 2023, Outsourcing UK regulatory decisions – A double edged sword?, The Lancet, Vol:402, ISSN:0140-6736, Pages:24-25

Lythgoe M, 2023, The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020, International Journal of Cancer, Vol:152, ISSN:0020-7136, Pages:2474-2484

More Publications